Abstract
We report a case study of a patient with a clinical diagnosis of Post-traumatic Stress Disorder (PTSD) referred to a neurochemistry Magnetic Resonance Spectroscopy (MRS) study. The clinical evaluation prior to scanning suggested the presence of PTSD, Major Depressive Disorder (MDD) accompanied by suicidal ideation. MRS prior to and at the completion treatment and 12-weeks post treatment identified neurotransmitters consistent with a diagnosis of PTSD and MDD. The neurochemistry evaluation immediately post-treatment identified levels that compared to healthy subjects while at 12-weeks post-treatment the neurochemistry reflected a recurrence of depressive symptoms that were described by the patient. These results offer the potential for neurochemical markers to monitor the response of an individual to therapy.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
